Arrowhead Pharmaceuticals Stock Discussion

The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.

The company's P/S ratio is high in contrast to its lower projected growth, a divergence that could bring risk to shareholders and potential investors. The current P/S ratio might not sustain due to predicted future revenues.

High level of risk for Arrowhead Pharmaceuticals with negative EBIT and a dip in free cash flow. The company burnt US$331m, reported a US$205m loss raising capital raising flags. Investors monitor balance sheet and warning signs needed.

Javier San Martin's insider sale at current price level is not a major concern, nor a positive sign. The lack of insider buying over the past year and mediocre level of insider ownership warrant caution in purchasing its stock.